ADC Therapeutics SA Share Price

ADC Therapeutics SA Share Price

NYSE: ADCT | Micro Cap
$1.35
+$0.08 (6.30%) Last updated on 18 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

ADC Therapeutics SA Stock Performance

Open
$1.25
Prev. Close
$1.27
Circuit Range
N/A
Day Range
$1.25 - $1.41
Year Range
$0.78 - $4.96
Volume
76,084
Average Traded
$1.35

ADC Therapeutics SA Share Price Today

As of 18 November 2026, ADC Therapeutics SA's share price is $1.35. The stock opened at $1.25, compared to its previous close of $1.27. During today's trading session, ADC Therapeutics SA's share price traded between $1.25 and $1.41, with an average price of $1.33. Over the past 52 weeks, the stock has recorded a high of $4.96 and a low of $0.78. In terms of performance, ADC Therapeutics SA's share price has declined by 60.29% over the last six months and is down 68.60% on a year-on-year basis.

ADC Therapeutics SA Share Price Chart

Line chart of the ADC Therapeutics SA price trend over the selected period. The price rose overall, ranging from 1.25 to 1.41, ending at 1.35.
$1.25$1.41
L
Show Current Price
H

ADC Therapeutics SA Stock Fundamentals & Key Indicators

Market Cap
$171.54M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.58
Revenue (TTM)
$81.36B
Return On Equity (TTM)
32.61%
Profit Margin
-175.29%
Debt to Equity
-0.47
Quarterly Earnings Growth YoY
-294.70%

ADC Therapeutics SA Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$23.06$20.85$19.25$21.72
Net Profit-$6.41-$32.97-$16.57-$25.30
Net Profit Margin-27.80%-158.13%-86.08%-116.48%
Income ChangeN/A-414.35%49.74%-52.69%

ADC Therapeutics SA Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$209.91$69.56$70.84$81.36
Net Profit-$157.13-$240.05-$157.85-$142.62
Net Profit Margin-74.86%-345.10%-222.83%-175.29%
Income ChangeN/A-52.77%34.24%9.65%

About ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

ADC Therapeutics SA Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$1.57
$1.35
-11.15%
Oct 2026
$1.19
$1.52
+26.03%
Sep 2026
$1.17
$1.21
+8.52%
Aug 2026
$1.06
$1.11
+6.19%
Jul 2026
$1.07
$1.05
-0.94%
Jun 2026
$3.42
$1.06
-68.82%
May 2026
$3.77
$3.40
-9.93%
Apr 2026
$3.75
$3.77
+0.80%
Mar 2026
$3.99
$3.75
-8.66%
Feb 2026
$3.65
$4.10
+13.26%
Jan 2026
$3.50
$3.62
+2.40%
Dec 2025
$4.26
$3.54
-17.79%

ADCT Share Price FAQs